Adventrx: CoFactor, Uftoral had greater growth inhibition of colorectal tumors

By E. Janene Geiss

Philadelphia, Sept. 18 - Adventrx Pharmaceuticals, Inc. said Monday that new data demonstrated that, in mice with metastatic colorectal cancer, treatment with CoFactor in combination with Uftoral resulted in greater inhibition of tumor growth and longer median survival time than treatment with Uftoral-plus-leucovorin or Uftoral alone.

CoFactor is a folate-based drug designed to improve the efficacy and safety of the anticancer agent 5-fluorouracil (5-FU). Uftoral, an oral anticancer drug approved for use in Asia and Europe, delivers a combination of tegafur, a prodrug of 5-FU, and uracil, according to a news release from the San Diego biopharmaceutical company.

In the study with mice, tumor treatment with CoFactor plus Uftoral resulted in the greatest inhibition of tumor growth among the three treatment groups, as well as the control group.

The data were presented at a joint meeting of the Asian Clinical Oncology Society & the Chinese Society of Clinical Oncology on Saturday in Beijing.

These results are further evidence of CoFactor's improved ability over leucovorin to increase the effectiveness of fluoropyrimidines, company officials said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.